1. A class action lawsuit against Organon claims securities fraud. 2. The lawsuit pertains to misleading statements about Organon's financial priorities. 3. Organon cut its quarterly dividend by 70%, resulting in a stock price drop. 4. Stock fell from $12.93 to $9.45, a decline of over 27% in one day. 5. Investors can seek compensation without out-of-pocket costs.
The drastic drop in stock price indicates severe investor confidence loss, similar to past cases like PG&E's bankruptcy announcement, which resulted in massive stock declines.
The article addresses a significant legal challenge to OGN, which could materially affect investor sentiment and stock price, leading to heightened volatility.
The immediate impact from the lawsuit and dividend cut will likely affect OGN's stock performance in the short term, similar to how past announcements have led to immediate market reactions.
Levi & Korsinsky, LLP notifies investors in Organon & Co. ("Organon" or the "Company") (NYSE: OGN) of a class action securities lawsuit.
The lawsuit seeks to recover losses on behalf of Organon investors who were adversely affected by alleged securities fraud between October 31, 2024 and April 30, 2025. Follow the link below to get more information and be contacted by a member of our team:
https://zlk.com/pslra-1/organon-co-lawsuit-submission-form?prid=152224&wire=4
OGN investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Organon's priorities, particularly, related to capital allocation through quarterly dividends. Notably, defendants concealed the high priority of Organon's debt reduction strategy following the Company's acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly dividend. Following this news, the price of Organon's common stock declined dramatically. From a closing market price of $12.93 per share on April 30, 2025, Organon's stock price fell to $9.45 per share on May 1, 2025, a decline of more than 27% in the span of just a single day.
If you suffered a loss in Organon during the relevant time frame, you have until July 22, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE Levi & Korsinsky, LLP